KPV is a tripeptide — lysine-proline-valine — derived from the C-terminal sequence of alpha-melanocyte-stimulating hormone (alpha-MSH). Despite its small size, it carries the core anti-inflammatory activity of the parent hormone while shedding the pigmentation and hormonal effects associated with full-length alpha-MSH. This selectivity makes KPV one of the most focused anti-inflammatory research peptides available.
KPV and Alpha-MSH: Understanding the Relationship
Alpha-MSH is a naturally occurring neuropeptide produced by the pituitary gland and peripheral tissues. It exerts potent anti-inflammatory effects through melanocortin receptors, particularly MC1R and MC3R. KPV represents the minimal active fragment of alpha-MSH — specifically residues 11-13 — that retains the full anti-inflammatory signalling capacity without activating the MC1R pathway responsible for melanogenesis.
Critically, KPV can enter cells directly via the organic cation transporter-1 (OCT-1) and exert intracellular anti-inflammatory effects, bypassing the need for surface receptor binding. This intracellular activity is particularly relevant for gut epithelial research.
IBS and Gut Inflammation Research
The gastrointestinal tract is where KPV research has been most extensively conducted. In animal models of inflammatory bowel disease and colitis, KPV administration significantly reduced mucosal inflammation, restored epithelial barrier integrity, and decreased pro-inflammatory cytokine production — including IL-1beta, IL-6, and TNF-alpha. Notably, oral administration produced detectable anti-inflammatory effects, which is unusual for a peptide given the normally hostile digestive environment.
This oral stability appears to be a function of KPV's small size and specific amino acid composition. Researchers studying IBS models have observed that KPV reduces mast cell activation in colonic tissue — a key driver of the pain and motility disturbances characteristic of IBS.
Wound Healing and Skin Inflammation
KPV has been studied in topical wound healing models where its anti-inflammatory properties translate to accelerated closure, reduced granulation tissue formation, and lower rates of inflammatory complications. It downregulates NF-kB signalling in keratinocytes and dermal fibroblasts, suppressing the inflammatory cascade that can impede healing. Some researchers pair KPV with BPC-157 for a synergistic approach to gut or tissue healing research — BPC-157 contributing pro-angiogenic and growth factor upregulation while KPV controls the inflammatory environment.
Systemic Anti-Inflammatory Mechanisms
Beyond the gut and skin, KPV inhibits NF-kB nuclear translocation across multiple cell types, reducing the transcription of a broad array of pro-inflammatory genes. It also downregulates MAPK signalling pathways, providing a secondary mechanism of inflammatory suppression. These broad mechanistic effects have driven interest in KPV for neuroinflammation research, though this remains a less mature area compared to gut and wound applications.
Research Dosage Protocol
Standard research dosage: 500 mcg – 1 mg per day
Administration: Subcutaneous injection after reconstitution with bacteriostatic water. Use the BAC water calculator to prepare your working solution. Oral capsule formulations have also been used in gut-targeted research, exploiting KPV's relative oral stability.
Storage: Lyophilised powder at -20°C; reconstituted solution at 4°C, use within 4 weeks.
Where to Buy KPV in India
Peptide Central stocks KPV at 99% purity, independently HPLC-verified with a full Certificate of Analysis included. Pan-India delivery with COD available. For researchers exploring gut healing protocols, KPV pairs well with BPC-157 — together they address both the inflammatory and structural repair dimensions of gastrointestinal research.